In the unpredictable theater of global finance, few figures command attention quite like Donald J. Trump. His pronouncements, often delivered with the subtlety of a sledgehammer, consistently send ripples, if not tidal waves, through the stock markets. The closing weeks of 2025 have proven no exception, offering a fresh batch of market-moving maneuvers that leave analysts scratching their heads and investors reaching for their antacids. From “historic” drug price cuts that somehow boost pharma stocks to a s ...

President Donald Trump on Friday unveiled a sweeping set of drug-pricing agreements with nine major pharmaceutical companies, presenting the initiative as a cornerstone of his effort to bring American medicine costs closer to those paid in Europe.The announcement marked a significant expansion of the administration’s pricing push, with Trump confirming that deals have now been struck with 14 of the 17 drugmakers he formally pressed in July to lower prices. Central to the strategy is the launch of a new dire ...

UnitedHealth Group (NYSE: UNH) has endured a brutal 2025, with shares down approximately 35% year-to- date. This marks the company's worst annual performance since 2008, when it lost more than 54% during the financial crisis. The stock reached a 52-week low around $235 in August before rebounding roughly 46% to its current levels near $328. Despite this sharp decline — or precisely because of it — the depressed valuation has created an attractive entry point for investors. Trading at a forward P/E ratio 18 ...

I'd like to see the money that is going to the insurance companies by the hundreds of billions of dollars. The stocks are up through the roof over a fairly short period of time because they're getting vast amounts of money. I want that money to go to the people directly and let the people buy their own health care and uh they'll get much better health care than they get with the unaffordable care act. let the money go directly to the people and let them buy their own healthcare.>> President Trump along with ...

UnitedHealth said on Friday that audits by outside consulting firms of its health services and pharmacy benefit units would result in operational changes including more automation and increased standa... ...

Elevance Health, Inc. (NYSE:ELV) is included among the 12 Best Long Term US Stocks to Buy Now. BofA Adjusts Elevance Health (ELV) Target to Reflect Higher Sector Valuations On December 16, BofA lifted its price target on Elevance Health, Inc. (NYSE:ELV) to $385 from $370 and kept a Neutral rating. The firm noted that its higher target reflects richer multiples across the peer group. Elevance Health, Inc. (NYSE:ELV)’s third-quarter results showed steady execution. The benefit expense ratio landed where m ...

公司概况与市场地位 - 公司是医疗保健行业的知名企业，提供一系列健康保险产品和服务，尤其以医疗保险计划闻名，在美国医疗保健市场占据重要地位 [1] - 公司的主要竞争对手包括联合健康集团和Anthem等其他大型保险公司 [1] - 公司当前市值约为313亿美元，体现了其在医疗保健行业的重要地位和规模 [5] 近期股价表现与交易情况 - 公司当前股价为260.28美元，日内上涨2.12美元，涨幅0.82% [4] - 日内股价波动区间为256.35美元至266.08美元 [4] - 过去52周，股价波动区间为206.87美元至315.35美元 [4] - 今日交易量为1,073,203股，显示出活跃的投资兴趣 [5] 分析师观点与价格目标 - 摩根士丹利分析师Erin Wright于2025年12月18日为公司设定了262美元的目标价 [2] - 该目标价发布时，股价为260.28美元，意味着潜在上涨空间为0.66% [2] - 分析师设定的目标价反映了对公司未来表现的信心 [2] 重大合同与政府合作 - 美国国防部授予公司一份价值73亿美元的合同，涉及提供医疗保健和行政支持服务 [3] - 该合同凸显了公司与五角大楼的持续合作伙伴关系，并强化了美国政府对公司的高度信任和依赖 [3] - 该合同巩固了公司在医疗保健领域的强势地位 [3]

公司评级与股价动态 - 摩根士丹利将Humana的评级定为“跑输大盘”，并将其目标股价从277美元下调至262美元 [1][6] - 尽管被下调评级，公司股价仍展现出韧性，于2025年12月18日上涨2.12美元，涨幅0.82%，收于260.28美元 [2] - 公司股票日内交易区间在256.35美元至266.08美元之间，过去52周股价最高为315.35美元，最低为206.87美元 [4] 重大合同与财务表现 - 公司获得美国国防部一份价值73亿美元的医疗保健和行政支持服务合同，凸显了其与五角大楼的稳固关系 [3][6] - 该重大合同可能对公司未来的财务表现产生积极影响 [3][5] - 公司当前市值约为313亿美元，体现了其在健康保险行业的重要地位 [4] 市场交易与投资者关注 - 公司当日成交量为1,073,203股，反映了投资者对该股票的兴趣 [5] - 尽管评级负面，但新获的国防部合同可能为公司未来的增长和稳定性提供积极前景 [5][6]

Key Takeaways CLOV is gaining share with 35% membership growth and nearly 50% revenue growth, backed by retention above 90%.CLOV sees higher margins as Clover Assistant drives profits and improves cost ratios for returning members.CLOV expands monetization through Counterpart Health, extending its platform beyond Medicare Advantage plans.Clover Health Investments (CLOV) is well poised for growth in the coming quarters, courtesy of its broad product spectrum. This optimism is primarily driven by its technolo ...

is House Minority Leader Hakee Jeff. Uh good morning to you. You heard the president uh last night.He says the Democrats are in the pockets of the insurance companies uh and that the price of uh your healthcare is actually going to go down under his plan. What say you. >> Well, good morning.Great to be with you. Uh the Republican health care crisis is devastating the American people and Donald Trump has zero credibility on the issue of healthcare. This is the party that has enacted the largest cut to Medica ...